相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
The role of complete response in multiple myeloma
Jean-Luc Harousseau et al.
BLOOD (2009)
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
Antje Hoering et al.
BLOOD (2009)
Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma
Andrzej J. Jakubowiak et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
C. B. Reeder et al.
LEUKEMIA (2009)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Bortezomib:: an effective agent in extramedullary disease in multiple myeloma
R Laura et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
H Hassoun et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial
E Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effect of age on immunoglobulin A subclass distribution in human parotid saliva
NK Childers et al.
ORAL MICROBIOLOGY AND IMMUNOLOGY (2003)
Reliability of measuring iliac crest level in the standing and sitting position using a new measurement device
SR Piva et al.
JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS (2003)
Euglycaemic diabetic ketoacidosis
RG Davies et al.
HOSPITAL MEDICINE (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
